In addition, studies in breast cancer models have shown that withdrawal of CCL2 inhibitors triggers massive monocyte mobilization, cancer cell activation, and IL-6/VEGF-A-driven metastatic recurrence, whereas concurrent blockade of CCL2 and IL-6 significantly inhibits metastasis and extends survival (225). This evidence concerns the gene CCL2 and breast carcinoma.